Head and Neck Neuroendocrine Carcinoma — Research

Head and Neck Neuroendocrine Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	8	`("Head and Neck Neuroendocrine Carcinoma"[tiab] OR "Head and Neck Neuroendocrine Cancer"[tiab] OR "Primary Head and Neck Neuroendocrine Carcinoma"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	8	`("Head and Neck Neuroendocrine Carcinoma"[tiab] OR "Head and Neck Neuroendocrine Cancer"[tiab] OR "Primary Head and Neck Neuroendocrine Carcinoma"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	4	`("Head and Neck Neuroendocrine Carcinoma"[tiab] OR "Head and Neck Neuroendocrine Cancer"[tiab] OR "Primary Head and Neck Neuroendocrine Carcinoma"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (13)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 1–13 of 13 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
· N Engl J Med · 2023 · PMID 37870969 · validated civic_curation pubmed
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
· N Engl J Med · 2020 · PMID 32846061 · validated civic_curation pubmed
When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
· Ann Surg Oncol · 2009 · PMID 19472011 · validated civic_curation pubmed
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
· Cancer · 2016 · PMID 27525386